Alexandre Brossard

Alexandre Brossard has extensive work experience in the pharmaceutical industry. Alexandre started their career at Pall Life Sciences as an intern, where they developed a high throughput screening method for monoclonal antibody purification processes. Alexandre then interned at Astra Zeneca, where they worked on the production and purification of antibody fragments and optimized purification and crystallization protocols for protein IL-17A.

Brossard later joined GSK, where they completed the Global Industrial Operations Graduate program. Alexandre gained experience in production, filling, process transfer, and quality assurance in various locations around the world. Alexandre also served as a New Product Introduction Formulation Supervisor, leading a team to produce vaccines for clinical trials.

After GSK, Brossard joined Ablynx as a CMC Associate Project Leader, overseeing the drug substance development of Caplacizumab. Currently, they hold the position of CMC Senior Scientist at arGEN-X, a role they started in February 2021. In April 2023, they were promoted to the position of CMC Drug Substance Principal Scientist.

Alexandre Brossard obtained a Master Degree in Biotechnology from ENSTBB Bordeaux INP between 2009 and 2012. Prior to that, they attended Lycée Le Fresnes preparatory school (BCPST) from 2007 to 2009, focusing on Biology, Chemistry, Physics, and Earth sciences.